Evaluation of Naltrexone as a Treatment for Self-Injurious Behavior

Trial Profile

Evaluation of Naltrexone as a Treatment for Self-Injurious Behavior

Withdrawn prior to enrolment
Phase of Trial: Phase IV

Latest Information Update: 09 Nov 2017

At a glance

  • Drugs Naltrexone (Primary)
  • Indications Self-injurious behaviour
  • Focus Therapeutic Use
  • Acronyms NTX-SIB
  • Most Recent Events

    • 31 Oct 2017 Planned End Date changed from 1 Sep 2018 to 4 Jan 2017.
    • 31 Oct 2017 Planned primary completion date changed from 1 Sep 2017 to 30 Jun 2015.
    • 31 Oct 2017 Planned initiation date changed from 1 Sep 2016 to 22 Feb 2014.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top